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The optimal perioperative anticoagulation management in
patients on warfarin therapy is poorly defined due to the lack
of randomized trials. Because guidelines are heterogeneous,
it was hypothesized that “treatment strategies are not uniform
in clinical practice”. Between February 2003 and May 2003,
a questionnaire with 4 different clinical scenarios was dis-
tributed to physicians by e-mail, or direct contact was made
by a survey monitor. Two scenarios described the cases of
patients with a mechanical heart valve (MHV) in the mitral
position, with additional risk factors for a systemic
embolism; one undergoing major (scenario 1) and the other
minor surgery (scenario 3). Two scenarios described patients
with an aortic MHV; one undergoing major (scenario 2) and
the other minor (scenario 4) surgery. Different preoperative
and postoperative management options were offered. The
treatment options for all scenarios were the same. Of the 90
questionnaires distributed, 52 (57.8%) were returned. Hospi-
talization for full-dose intravenous unfractionated heparin (IV
UH) was the most commonly selected strategy in the
preoperative phase for scenarios 1 (59%), 2 (42%) and 3
(44%). In scenario 4, 34% chose IV UH. Outpatient, full-
dose, subcutaneous UH or low-molecular-weight heparin
(LMWH) was the most selected option in the postoperative
phase for all scenarios, with the exception of number 4
(52.9% in scenario 1, 34% in scenario 2, 32%, in scenario
3 and 28% in scenario 4). Even among expert clinicians, the
management of perioperative anticoagulation is heterogene-
ous. In particular, the definition of risk categories and the
optimal intensity of antithrombotic drugs need to be defined
by well-designed prospective studies.
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INTRODUCTION
The management of the patients with chronic
oral anticoagulation during invasive procedures is
problematic. Clinical guidelines and reviews have
proposed strategies for perioperative anticoagula-
tion in chronically anticoagulated patients.
1-6
However, published recommendations are incons-
istent, and not based on well-designed clinical
trials. Thus, the relative efficacy and safety of dif-
ferent perioperative management strategies re-
mains unknown.
The risk of postoperative bleeding is related to
the adequacy of postoperative hemostasis, the
type of procedure, age and the presence of malig-
nancy.
4 Conversely, the risk of postoperative
thromboembolism is determined by the type of
procedure, the clinical consequence of recent
thromboembolic event, age and the presence of
additional thromboembolic risk factors such as
malignancy, antiphospholipid syndrome or hered-
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itary thrombophilic disorders.
4
The management of patients with mechanical
heart valves is of particular concern to treating
physicians. There is also considerable controversy
and variation in the recommendations for the
prevention of thromboembolism in such patients.
Kearon and Hirsh
7 suggested that approximately
8 thromboembolic events per 100 patient-years
would occur in patients with uncomplicated me-
chanical valvular prostheses following temporary
discontinuation of oral anticoagulants. This risk is
much lower than that of patients with a recent
episode of deep venous thrombosis (40 cases per
hundred patient-years) or arterial thrombosis (15
cases per hundred patient-years). Improvements
in prosthetic materials and valve designs have
reduced the risk of thromboembolic complica-
tions.
8 In the most recent version of the guidelines
of the American College of Chest Physicians
Consensus Conference on Antithrombotic therapy
(ACCP), otherwise healthy patients with a
bileaflet or tilting disk valve in the aortic position
are considered to be at such low risk of throm-
boembolism that perioperative anticoagulants are
deemed unnecessary when warfarin is interrupted
for short time periods.
3 On the contrary, because
patients with a mechanical heart valve in the
mitral position are thought to be at high risk, full
dose UH or LMWH is recommended.
3 Very simi-
lar recommendations were previously published
by the American College of Cardiology (ACC).
2
However, a distinction in the risk of throm-
boembolic events between mechanical valves in
the aortic and mitral positions when oral
anticoagulants are temporarily interrupted has not
been universally accepted.
In light of the absence of well-designed pro-
spective studies, and the lack of uniformity
among clinical guidelines, the hypothesis that “the
perioperative anticoagulation management of
patients with mechanical heart valves would be




Between February 2003 to May 2003, a question-
naire with 4 different clinical scenarios (Table 1)
was distributed to physicians by e-mail, or direct
contact was made by a monitor. Only physicians
regularly involved in making recommendations
about perioperative anticoagulation from uni-
versity hospitals were chosen. Two scenarios de-
scribed the patients with a mechanical heart valve
(MHV) in the mitral position, with additional risk
factors for a systemic embolism: one undergoing
major (scenario 1) and the other minor surgery
(scenario 3). Two scenarios described patients
with an aortic MHV, one undergoing major
(scenario 2) and the other undergoing minor
(scenario 4) surgery. Different preoperative and
postoperative management options were offered.
Treatment options for all scenarios were the same.
The questionnaire begins with 5 questions aimed
at describing the training and role of the partici-
pants involved. In particular, participants were
asked about the type of specialties of physicians,
the frequency with which they make recommen-
dations about perioperative anticoagulation,
whether or not they are affiliated with an Anticoa-
gulation Clinic or Anticoagulation Service, and
finally, about whether a guideline exists that
addresses the management of patients when oral
Table 1. Clinical Scenarios
1. A 70-year-old woman, with a mechanical mitral valve, chronic atrial fibrillation, and a previous stroke two years
ago, is to undergo elective (open) subtotal colectomy for resection of an adenocarcinoma of the colon.
2. A 65-year-old man, with a mechanical bileaflet aortic valve, is to undergo an elective (open) subtotal colectomy
for resection of an adenocarcinoma of the colon. He has no other medical problems.
3. A 75-year-old man, with a mechanical mitral valve, a previous stroke 3 years ago and chronic atrial fibrillation,
is to undergo an elective bilateral inguinal hernia repair.
4. A 48-year-old woman, with a mechanical bileaflet aortic valve, is to undergo anelective bilateral inguinal hernia
repair. She has no other medical problems.Doyeun Oh, et al. 68
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anticoagulant therapy needs to be interrupted for
a procedure exists. All answers were anonymous.
The first scenario described “a 70-year-old
woman, with a mechanical mitral valve, chronic
atrial fibrillation, and a previous stroke two years
earlier, who was to undergo an elective (open)
subtotal colectomy for resection of an adenocar-
cinoma of the colon”. The second scenario de-
scribed “a 65-year-old man, with a mechanical
bileaflet aortic valve, who was to undergo an
elective (open) subtotal colectomy for resection of
an adenocarcinoma of the colon, but had no other
medical problems”. The third scenario described
“a 75-year-old man, with a mechanical mitral
valve, a previous stroke 3 years earlier and
chronic atrial fibrillation, who was to undergo an
elective bilateral inguinal hernia repair”. The
fourth scenario described “a 48-year-old woman,
with a mechanical bileaflet aortic valve, who was
to undergo an elective bilateral inguinal hernia
repair but had no other medical problems”. For
each of the 4 scenarios presented, 4 options were
proposed for the preoperative management and 5
or the postoperative management of the patients.
The anticoagulation options are presented in
Table 2.
Comparison of anticoagulant management
preferences of Korean and Canadian surveys
The preoperative and postoperative options for
each scenario were compared between Korean
and Canadian surveys that used the same sce-
narios. the Canadian data presented in Figure 2




Of the 90 questionnaires distributed, 52 (57.8%)
were returned. Of the 52 physicians responding to
the questionnaire, cardiologists were the best
represented (n=21, 41.2%), followed by hemato-
logists (n=13, 25%), cardiac or vascular surgeons
(n=12, 23.5%) and internists (n=3, 5.9%). Forty-one
of the participants returning the questionnaire
(78.5%) were affiliated with an Anticoagulation
Clinic or an Anticoagulation Service. Of these, 35
(83.3%) reported that they used local guidelines to
decide upon the perioperative management
strategy when oral anticoagulant therapy was
temporarily discontinued.
The results from the survey are shown in Fig.
1. The first scenario described a patient with a
high thromboembolic risk undergoing a surgical
procedure considered high risk for both throm-
botic and hemorrhagic complications. Admission
to hospital for full-dose IV UH was the most fre-
quently selected anticoagulation option for pre-
operative anticoagulation (n=30, 58.8%), followed
by “outpatient full-dose subcutaneous (SC) UH or
LMWH” (n=17, 33.3%) and “nothing else other
than holding warfarin” (n=3, 5.9%). One physician
selected “low-dose subcutaneous UH/LMWH”.
For the postoperative management, “full-dose SC
Table 2. Anticoagulation Options
Preoperative options
(A) Admit to hospital 2 to 4 days preop for full-dose heparin
(B) Outpatient full-dose SC heparin or LMWH
(C) Nothing else other than holding warfarin preoperatively
(D) Another anticoagulation strategy
Postoperative options
(A) Full-dose in-hospital IV heparin until INR therapeutic
(B) Full-dose SC heparin or LMWH until INR therapeutics
(C) Low-dose in-hospital or outpatient SC heparin or LMWH until INR therapeutics
(D) Nothing else other than re-starting warfarin postoperatively
(E) Another anticoagulation strategyPerioperative Anticoagulation in Patients with Mechanical Heart Valve 69
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UH or LMWH” was the most frequently selected
anticoagulation option (n=27, 52.9%), followed by
“full-dose intravenous UH” (n=17, 33.3%). Six
physicians (11.8%) selected “low-dose SC UH or
LMWH” and one “nothing else other than re-
starting warfarin” after the operation. No physi-
cian selected an alternative anticoagulation strat-
egy.
The second scenario described a patient at low
risk of thromboembolic events, according to the
last ACCP guidelines,
3 undergoing a surgical pro-
cedure considered high risk for both thrombotic
and hemorrhagic complications. For the pre-
operative management, admission of intravenous
full-dose UH (n=21, 42%) and full-dose LMWH
(n=21, 42%) were the two most frequently selected
anticoagulation options, followed by “nothing else
other than holding warfarin” (n=5, 10%). Three
physicians selected outpatient low-dose SC UH
and one did not respond. For the postoperative
management, both full-dose SC and low-dose UH
or LMWH were the two most frequently selected
anticoagulation options (n=17, 34%), followed by
full-dose intravenous UH(n=14, 28%). Two physi-
cians (4%) selected nothing else other than re-
starting warfarin after the operation and one did
not respond.
The third scenario described a man at high risk
for thromboembolic complications undergoing a
low risk surgical procedure. For the preoperative
management, 22 participants (44%) selected intra-
venous full-dose UH (n=22, 44%), followed by
full-dose LMWH (n=21, 42%) and nothing else
other than holding warfarin (n=5, 10%); two
respondents chose low-dose SC UH and one did
not respond. For the postoperative management,
hospitalization for intravenous full-dose UH (n=
16, 32%) and full-dose SC or LMWH (n=16, 32%)
and low-dose SC or LMWH (n=15, 30%) were the
most frequently selected anticoagulation options.
Three physicians (6%) selected nothing else other
than re-starting warfarin postoperatively.
The fourth scenario described a woman at low
embolic risk, according to the ACCP guidelines,
undergoing a low risk surgical procedure. For the
preoperative management, outpatient full-dose
LMWH (n=24, 48%) was the most frequently se-
lected anticoagulation option, followed by admin-
istered full dose subcutaneous UH (n=17, 34%)
and nothing else other than holding warfarin
(n=6, 12%). Three physicians selected outpatient
low-dose subcutaneous UH and one did not
respond.
For the postoperative management, 17 parti-
cipants (34%) selected low-dose subcutaneous UH
or LMWH, followed by full-dose subcutaneous
UH or LMWH (n=14, 28%), and full-dose intra-
venous UH (n=12, 24%). Seven physicians (14%)
indicated they would simply reintroduce warfarin
without administering any additional antithrom-
botic treatment.
The preoperative and postoperative choices for
each scenario were compared with the results
from a 1997 distribution of this survey to Cana-
dian providers (Fig. 2). Compared to the Canadian
physicians, the Korean physicians chose LMWH
Fig. 1. Preoperative (A) and postoperative (B) anticoagulation management preferences of Korean physicians. 1, 2, 3 and
4 represent the clinical scenarios described in Table 1. A, B, C, D and E represent the anticoagulant options described in
Table 2.
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more frequently in all four scenarios.
DISCUSSION
In this survey, the physician preferences for the
perioperative anticoagulation management of
patients with mechanical heart valves were inves-
tigated. Three main issues were raised by our
results. (1) Guidelines
2,3 suggesting patients with
a mechanical aortic valve do not need any
perioperative anticoagulation are not universally
accepted. (2) There is no clear consensus on the
peri-operative management of patients receiving
oral anticoagulant treatment. (3) LMWH has been
increasingly accepted as a perioperative anticoa-
gulant for patients whose oral anticoagulant
therapy must be interrupted.
In recent years, long-term follow up studies
have shown that patients with a bileaflet valve (St.
Jude Medical or Carbomedics) or tilting disk valve
(Medtronic-Hall) in the aortic position, and who
were in a normal sinus rhythm and have a left
atrium of normal size, were at low risk of a
systemic embolism,
10-12 so a lower INR range,
between 2.0 and 3.0, is now recommended.
13
However, whether this finding implies a lower
risk of a systemic embolism during the short
intervals when warfarin has been discontinued
needs to be confirmed by well-designed prospec-
tive studies.
The answers to our questionnaire revealed a
substantial variability in the choice between full
and low dose UH or LMWH in both the high and
low risk situations. Intravenous full dose heparin
was the most frequently selected anticoagulant
option, especially in patients with a very high
thrombotic risk: 58.8% of participants prescribed
full dose UH in the preoperative phase for
patients with a mitral valve prosthesis and history
of stroke. Conversely, the responses for patients
with lower thrombotic risk were less uniform. In
Fig. 2. Comparison of preoperative (A, upper panels) and postoperative (B, lower panels) anticoagulation management
preferences of Korean and Canadian physicians. 1, 2, 3 and 4 represent the clinical scenarios described in Table 1. A, B,
C, D and E represent the anticoagulant options described in Table 2.
A B
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the preoperative phase, for a patient with a me-
chanical aortic valve and no concomitant throm-
botic risk factor, 34% of participants prescribed
full-dose UH, whereas 48% prescribed LMWH
and 18% no or lower dose heparin until restarting
warfarin postoperatively. For all four scenarios,
the rate of participants selecting full-dose intra-
venous UH decreased from the preoperative to
the postoperative phases, from 58.8 to 33.3% in
the first scenario, 42 to 28% in the second, 44 to
32% in the third, and from 34 to 24% in the forth.
Apparently, when warfarin is reintroduced many
physicians feel comfortable in administering
subcutaneous LMWH/UH instead of intravenous
full-dose UH until the INR reaches a therapeutic
range. It is possible they consider this strategy to
have a lower bleeding risk than IV UH during the
postoperative period.
Although full-dose intravenous UH is still
indicated by clinical guidelines,
2,3,5 LMWH is
gradually taking the place of UH in many clinical
settings. This acceptance is justified by the results
obtained in many trials comparing UH and
LMWH for the treatment of venous thromboem-
bolism and acute coronary syndromes.
14 Al-
though, evidence suggests that LMWH has com-
parable clinical efficacy and better cost-effec-
tiveness than intravenous UH as a perioperative
anticoagulant.
15-17 However, because the published
experience in this area consists of small uncon-
trolled cohort studies,
18-24 some physicians are still
reluctant to use LMWH, despite its advantages
over unfractionated intravenous UH as a peri-
operative anticoagulant.
The results of our survey are likely to be rele-
vant. Although, the answers were received from
only a small number of physicians, with most
regularly involved in making recommendations
about perioperative anticoagulation in their
hospitals, and many involved directly in the local
production of clinical guidelines for this purpose.
Thus, the results of our survey probably accu-
rately represent the Korean practice patterns.
In conclusion, there is still uncertainty on the
optimal perioperative management of chronic
anticoagulation patients having mechanical heart
valves. Prospective clinical trials will be required
to better guide clinicians in their choice of the
intensity and type of perioperative antithrombotic
strategies according to the thrombotic risk.
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